Compare
Gilead Sciences vs Halozyme (GILD vs HALO)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Halozyme (HALO) +51.7%; so far this year the figures are +36.0% and +54.0%.
Gilead Sciences is the larger company by market value, about 17.5 times the size of Halozyme.
Revenue grew +6.5% at GILD and +45.0% at HALO over the last year.
GILD yields 1.95%. HALO pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | HALO | |
|---|---|---|
| Price | $166.89 | $103.63 |
| 1-day | -0.41% | -15.72% |
| YTD | +35.97% | +53.98% |
| 1 year | +36.15% | +51.73% |
| 3 years | +108.12% | +209.25% |
| Market cap | $207.0B | $11.8B |
| P/E | — | 25.8 |
| P/S | 6.68 | 6.55 |
| P/B | 15.87 | — |
| Revenue growth | +6.50% | +45.00% |
| EPS growth | -149.00% | -15.60% |
| Gross margin % | 79.9 | 82.3 |
| Net margin % | -12.5 | 26.9 |
| ROE % | -29.6 | — |
| Debt / equity | 2.01 | — |
| FCF yield % | 6.7 | 7.5 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.59 |
| RSI (14) | 60.2 | 29.2 |
| Technical rating |